Center for Cell and Gene Therapy
@CAGTHouston
CAGT brings a wide variety of scientists and clinicians together to develop strategies for the treatment of cancer, HIV, and cardiovascular disease.
Congrats to our Director Katherine King on her Cell Stem Cell paper out today showing Tet2-mutant clonal hematopoiesis protects against Alzheimer’s disease. @BCMFromtheLabs @TCHResearchNews @CAGTHouston
🧵9/ We further show that: ✅ Effects were strongest💪🏽when both CAR and IL-15 signaling were active. ✅ Mutating⚡️CD3ζ ITAMs abrogated this effect. Therefore, CREM is a potent intracellular checkpoint that limits CAR-NK efficacy.
🧵1/ T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓. 📄Link: nature.com/articles/s4158… I’m so thrilled🥳to share our work out now🚨@Nature…
🔬"Approaches to target solid tumors and the tumor microenvironment with adoptive T cell therapies." Thank you Katie McKenna Ph.D. @McKenna_PhD17 for sharing your work with us! What approaches have you found effective in targeting solid tumors?📝

🧬🔬"Dynamic control of lineage identity to overcome CAR-driven T cell dysfunction". Thank you Nathan Singh MD for sharing your work with us! What strategies do you use to overcome T cell dysfunction?🤔#CancerResearch

Improving CD5 CART in T-ALL! @MaxMamonkin from @CAGTHouston explores strategies to enhance the clinical activity of CD5 CAR-T in T-ALL at #iwCART25. 🧬🔬 #TALL #CD5CART #Hematology
🧬"Opposing Effects of Dnmt3a and Tet2 Clonal Hematopoiesis on Alzheimer's Disease Pathogenesis" Thank you Katie Matatall PhD for sharing your work with us! Why do Dnmt3a and Tet2mutant HSCs have an advantage under inflammatory conditions? 👩🏼🔬#CancerResearch

In a follow-up of a phase 1 trial of a first generation CAR-T cell therapy in patients with neuroblastoma, 1 patient has had a sustained clinical response for over 18 years without requiring any additional therapy @MDKevinCHLi, @CAGTHouston @bcmHouston nature.com/articles/s4159…
Long-term #survival supports the potential benefit of #CARTcellTherapy to treat solid #tumors. #Cancer @NatureMedicine @bcmhouston @BCMCancerCenter @CAGTHouston blogs.bcm.edu/2025/02/27/fro…
🧬Cancer treatment study in Harris County aiming to bring more patients access to life-saving care! Martha Mims M.D. and Premal Lulla M.D. are working to provide cellular immunotherapy trials at Ben Taub. 👏 click2houston.com/news/local/202…
🧠🔬"Diverse roles for astrocytes in brain circuits in health and disease." Thank you Junsung Woo, Ph.D for sharing your work with us! Do you think astrocyte cells drive the healing process? #CancerResearch

In a follow-up of a phase 1 trial of a first generation CAR-T cell therapy in patients with neuroblastoma, 1 patient has had a sustained clinical response for over 18 years without requiring any additional therapy @MDKevinCHLi, @CAGTHouston @bcmHouston nature.com/articles/s4159…
Congratulations, Dr. K. King @TheKingLab, recipient of the 2025 @SocPedResearch Award in Honor of E. Mead Johnson recognizing outstanding #pediatricResearch achievements! @bcmhouston @TexasChildrens @TCHResearchNews #pediatricsInfectiousDisease societyforpediatricresearch.org/2025-award-rec…
It was an honor to be nominated by @Goodell_Lab as a @tamesttx protege and an even bigger honor to be selected as the ‘Science’ finalist for our work @CAGTHouston . Texas has a rich history of supporting medicine, engineering, science, and technology. Let’s keep it up!
Congratulations to our TAMEST 2025 Protégé Poster Challenge Finalists: - @BlairBenhamPyle, @bcmhouston - Nicholas Tran, Ph.D., @bcmhouston - Punith V. Shivaprasad, Ph.D., @Shell - @Guda_Lab, @UTSA #TAMEST2025